Early safety study of a new drug in healthy volunteers
Part of Digestive system clinical trials.
This early-phase trial tests a new drug called AD-230 in healthy adults to see how the body absorbs and processes it and to check for safety. You will help researchers learn important information before the drug is tested in patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 19 and 64 years old.
- You must be in good general health (this is a healthy-volunteer study).
- Your body mass index (BMI) must be between about 18.5 and 30. You can ask your doctor to check this.
- You cannot have taken part in another experimental-drug trial in the last 6 months.
- Other screening checks may apply.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new investigational drug called AD-230 in healthy adults. The main goal is to understand how the body processes the drug, check its safety, and see how food affects it.
This study tests a new medicine called AD-231 and compares it to taking three separate pills together. You would need to be in generally good health and within a certain age and weight range.
This trial tests two forms of a new medicine to see how safe they are and how the body handles them. It is for healthy adults aged 19 to 64, and participation helps gather important early information before the drug is studied in patients.
This study tests two new drugs in healthy adults to see how safe they are and how the body processes them. Taking part may help researchers learn if the drugs are safe for future use, though there is no direct benefit to you.
This trial tests a new drug called AD-123 and compares it to taking two other drugs (AD-1231 and AD-1232) together. It is for healthy adults to see how the body handles the drugs and if they are safe.
This trial tests a new drug (AD-115A or AD-1151) in healthy volunteers to see how safe it is and how the body processes it. If you qualify, you'll receive a single dose and be monitored closely.
Hear when a new Chronic Liver Disease (CLD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.